A federal judge in West Virginia denied Regeneron's request for an injunction against Amgen's Pavblu, creating uncertainty ...

Leerink Partners downgraded while Truist defended Regeneron (NASDAQ:REGN) after a judge denied the company’s motion for a preliminary injunction against Amgen (NASDAQ:AMGN) biosimilar for its ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) – Equities research analysts at Leerink Partnrs reduced their Q1 2025 EPS estimates for shares of Regeneron Pharmaceuticals in a ...

Fintel reports that on September 24, 2024, Leerink Partners downgraded their outlook for Regeneron Pharmaceuticals (WBAG:REGN) from Outperform to Market Perform. There are 2,433 funds or ...

Fintel reports that on September 24, 2024, Leerink Partners downgraded their outlook for Regeneron Pharmaceuticals (LSE:0R2M) from Outperform to Market Perform. There are 2,432 funds or ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stands against the other stocks to watch according to Jim Cramer. In a recent episode of Mad ...

Regeneron's Eylea has long dominated the ophthalmology ... s newly approved challenger Vabysmo have led analysts at SVB Leerink to slash their future sales estimates for the macular degeneration ...

Regeneron identifies new combos to boost I-O drug Libtayo's cancer response Ahead of the expected ASCO data release, analysts from Leerink Partners had hoped to see therapeutic doses inducing ...

In addition to Truist Financial, Regeneron also received a Buy from Oppenheimer’s Matthew Biegler in a report issued today. However, on January 28, Leerink Partners maintained a Hold rating on ...

Leerink cuts Regeneron stock price target to $762 from $880 Open in App ...